Inflexion’s experience in our sector, steering acquisitions and the immense task of carve-outs made them incredibly well suited to our ambitions. They bring substantially more than pure capital to our plans.
Guy Clark, CEO, CNX Therapeutics
CNX Therapeutics
In 2021 Inflexion acquired CNX Therapeutics, a European pharmaceutical company dedicated to the supply of essential medicines. The business was formed when Inflexion acquired Sunovion Pharmaceuticals Europe Limited, the European operations of US-based Sunovion.
-
-
Sector
Healthcare
-
Headquarters
London, UK
-
Fund
Buyout
-
Investment date
August 2021
-
Status
Current
The company
CNX Therapeutics is a European pharmaceutical company dedicated to the supply of essential medicines with a portfolio of speciality brands and hospital products.
The business was formed in August 2021 when Inflexion acquired Sunovion Pharmaceuticals Europe Limited, the European operations of US-based Sunovion. The carve out included the pan-European licensing rights to a patent-protected medicine used for the treatment of schizophrenia.
The Inflexion difference
With substantial experience in successfully executing carve-outs, Inflexion is drawing on its healthcare expertise to establish CNX Therapeutics as a standalone business. We are supporting CNX Therapeutics to build its product portfolio to develop a scaled European platform. This will focus heavily on hospital and central nervous system therapies that stand to benefit from its existing infrastructure and capabilities.